peptidefix

Peptides / Tesamorelin / United Kingdom

Tesamorelin in the United Kingdom

Legal status, what it is, and the listed suppliers in the United Kingdom that list it.

Legal status in the United Kingdom

Not an approved medicine. The MHRA products register returns no result for tesamorelin or Egrifta (checked 2026-09-22), and the EU marketing-authorisation application for Egrifta was withdrawn by the company.

As understood at 2026-09-22. Verify with the MHRA.

What Tesamorelin is

Tesamorelin is a synthetic, stabilised analogue of growth hormone-releasing hormone, the hypothalamic hormone that prompts the pituitary to release growth hormone. Unlike most substances covered on this site it is an approved medicine in the United States, sold as Egrifta, for one specific indication.

Full Tesamorelin page: targets and research →

Listed suppliers in the United Kingdom

6 of the 10 suppliers we list in the United Kingdom list Tesamorelin. Listed, not endorsed: each row is the supplier’s own stated terms.

Bluewell Peptides United Kingdom All Bluewell products are supplied strictly for laboratory research use only. They are not intended for human consumption, medical use, therapeutic use, diagnostic use, or veterinary use. Midshire Labs United Kingdom All Midshire Labs products are sold strictly for research purposes only. They are not intended for human consumption, medical, veterinary, or diagnostic use. Peptides Lab UK United Kingdom Strictly intended for laboratory research use only. Not for human or veterinary consumption. Pure Peptides UK United Kingdom All products are for research use only. Research Peptide United Kingdom Supplied strictly for research and laboratory use only and not for human or veterinary consumption. UK Peptides United Kingdom All products are sold exclusively for in-vitro research. They are not for human or veterinary use.

Clinical Research

Effects of Tesamorelin, a Growth Hormone-Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension
Falutz J, Potvin D, Mamputu JC, et al. (2010). JAIDS Journal of Acquired Immune Deficiency Syndromes. human 404 people with HIV on antiretroviral therapy with excess abdominal fat, randomised, double-blind, 12 months
Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Clinical Trial
Stanley TL, Feldpausch MN, Oh J, et al. (2014). JAMA. human 50 people with HIV on antiretroviral therapy with abdominal fat accumulation, randomised, double-blind, placebo-controlled, 6 months
Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial
Clemmons DR, Miller S, Mamputu JC (2017). PLOS ONE. human 53 people with type 2 diabetes, randomised to placebo or one of two tesamorelin groups, 12 weeks
Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity
Ellis RJ, Vaida F, Hu K, et al. (2025). The Journal of Infectious Diseases. human 73 people with HIV, virally suppressed, with abdominal obesity; phase 2, randomised, open-label against standard of care, 6 months